We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

31 hedge funds and large institutions have $3.77M invested in Lisata Therapeutics in 2018 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

137% more capital invested

Capital invested by funds: $1.59M → $3.77M (+$2.18M)

29% more funds holding

Funds holding: 24 → 31 (+7)

2.05% more ownership

Funds ownership: 5.76% → 7.81% (+2.1%)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

Holders
31
Holders Change
+7
Holders Change %
+29.17%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
4
Reduced
5
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$394K
2
Renaissance Technologies
Renaissance Technologies
New York
+$187K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$156K
4
Ameriprise
Ameriprise
Minnesota
+$131K
5
JP Morgan Chase
JP Morgan Chase
New York
+$86.6K

Top Sellers

Rank Fund Capital Flow
1
PAM
Panagora Asset Management
Massachusetts
-$180K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$6.03K
3
BlackRock
BlackRock
New York
-$1.59K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$69
5
UBS Group
UBS Group
Switzerland
-$69

LSTA Hedge Fund Activity: Q1 2018 in Review

31 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2018, worth a combined $3.77M — up 137% from $1.59M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new LSTA positions and 0 closed out — a net gain of 7 holders — while 4 added to existing stakes and 5 trimmed.

The largest buyer was Vanguard Group, adding an estimated $394K. The largest seller was Panagora Asset Management, cutting an estimated $180K.

  • 31 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2018, up from 24 in Q4 2017.
  • Funds reported $3.77M of Lisata Therapeutics stock for Q1 2018, up 137% quarter-over-quarter.
  • 7 funds opened new Lisata Therapeutics positions in Q1 2018 and 0 closed out, a net change of +7 holders.
  • The largest Lisata Therapeutics buyer in Q1 2018 was Vanguard Group, an estimated $394K added.
  • The largest Lisata Therapeutics seller in Q1 2018 was Panagora Asset Management, an estimated $180K sold.

Based on aggregated 13F filings for Q1 2018.